Apnimed, Inc. reported $125.935 million of Net Income for the quarter, while related-party Revenue declined to $12.080 million from $17.110 million. The results matter to investors because the company paired lower quarterly revenue with positive earnings, basic Earnings per share of $26.25 and Diluted Earnings per Share of $3.91.
Key Highlights
- Six-month related-party revenue reached $96.894 million, compared with $20.241 million in the comparable period.
- Six-month Research and Development expense fell to $18.004 million from $39.425 million.
- Money market funds stood at $36.476 million at June 30, 2026.
Apnimed, Inc. (NASDAQ: APMD) reported $125.935 million of net income for the three months ended June 30, 2026, while related-party revenue declined to $12.080 million from $17.110 million in the comparable period. Basic Earnings Per Share were $26.25, and diluted earnings per share were $3.91. The results cover the three months ended June 30, 2026 and June 30, 2025.
Quarterly Revenue And Earnings
Related-party revenue fell from $17.110 million in the comparable period to $12.080 million. Net income was $125.935 million, compared with a net loss of $69.474 million in the comparable period. Apnimed reported $126.113 million of net income from continuing operations for the quarter. Loss from discontinued operations was $178,000, compared with $63.847 million in the comparable period.
Expense Lines Move Differently
Research and development expense was $9.900 million for the quarter, down from $15.969 million in the comparable period. General and administrative expense increased to $12.674 million from $5.353 million. Cost of services from a related party was $1.210 million, compared with $1.724 million. Total operating expenses were $23.784 million, versus $23.046 million in the comparable period. Income from operations was a loss of $11.704 million, compared with an operating loss of $5.936 million. The quarter’s Operating Expense lines therefore showed lower research and development spending alongside higher general and administrative expense.
Six-Month Revenue Reaches $96.894M
For the six months ended June 30, 2026, related-party revenue was $96.894 million, compared with $20.241 million in the comparable period. Research and development expense was $18.004 million, down from $39.425 million. General and administrative expense reached $19.180 million, compared with $10.823 million. Cost of services from a related party was $3.370 million, versus $3.041 million. Total operating expenses for the six-month period were $40.554 million, compared with $53.289 million. Income from operations was $56.340 million, compared with an operating loss of $33.048 million. Six-month net income was $193.654 million, compared with a net loss of $98.120 million. Basic earnings per share were $40.38, while diluted earnings per share were $5.98.
Money Market Funds Total $36.476M
Money market funds totaled $36.476 million at June 30, 2026. The balance was included in cash and cash equivalents. Apnimed reported total stockholders’ Deficit of $195.456 million at June 30, 2026, compared with $72.873 million at the earlier balance-sheet date shown in the financial statements. As of September 4, 2026, 41,630,779 shares of common stock were outstanding.




Please wait processing your request...